Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy InterMune Inc (ITMN)?

Page 1 of 2

InterMune Inc (NASDAQ:ITMN) investors should be aware of an increase in enthusiasm from smart money in recent months.

In the 21st century investor’s toolkit, there are plenty of methods investors can use to analyze stocks. Two of the most useful are hedge fund and insider trading interest. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best hedge fund managers can outclass the market by a solid amount (see just how much).

InterMune Inc (NASDAQ:ITMN)

Equally as key, optimistic insider trading activity is a second way to break down the investments you’re interested in. Just as you’d expect, there are lots of motivations for a corporate insider to cut shares of his or her company, but just one, very clear reason why they would behave bullishly. Plenty of academic studies have demonstrated the market-beating potential of this strategy if you know where to look (learn more here).

Consequently, it’s important to take a glance at the recent action encompassing InterMune Inc (NASDAQ:ITMN).

How have hedgies been trading InterMune Inc (NASDAQ:ITMN)?

At Q1’s end, a total of 25 of the hedge funds we track were long in this stock, a change of 67% from one quarter earlier. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of notable hedge fund managers who were boosting their holdings considerably.

Of the funds we track, Sectoral Asset Management, managed by Jerome Pfund and Michael Sjostrom, holds the biggest position in InterMune Inc (NASDAQ:ITMN). Sectoral Asset Management has a $43.3 million position in the stock, comprising 1.3% of its 13F portfolio. On Sectoral Asset Management’s heels is Daniel Gold of QVT Financial, with a $37.4 million position; the fund has 2.5% of its 13F portfolio invested in the stock. Remaining peers that hold long positions include Steven Cohen’s SAC Capital Advisors, Jacob Gottlieb’s Visium Asset Management and Arthur B Cohen and Joseph Healey’s Healthcor Management LP.

With a general bullishness amongst the heavyweights, key money managers were leading the bulls’ herd. Visium Asset Management, managed by Jacob Gottlieb, established the most outsized position in InterMune Inc (NASDAQ:ITMN). Visium Asset Management had 27.2 million invested in the company at the end of the quarter. Arthur B Cohen and Joseph Healey’s Healthcor Management LP also made a $18.3 million investment in the stock during the quarter. The following funds were also among the new ITMN investors: Stephen DuBois’s Camber Capital Management, Sanford J. Colen’s Apex Capital, and Mark Kingdon’s Kingdon Capital.

What have insiders been doing with InterMune Inc (NASDAQ:ITMN)?

Bullish insider trading is best served when the company we’re looking at has seen transactions within the past six months. Over the last 180-day time frame, InterMune Inc (NASDAQ:ITMN) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s go over hedge fund and insider activity in other stocks similar to InterMune Inc (NASDAQ:ITMN). These stocks are Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), TESARO Inc (NASDAQ:TSRO), Clovis Oncology Inc (NASDAQ:CLVS), China Biologic Products Inc (NASDAQ:CBPO), and Dendreon Corporation (NASDAQ:DNDN). This group of stocks belong to the biotechnology industry and their market caps resemble ITMN’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!